



# WEBINAR

Tuesday, 29 September 2020

7.00–8.00 pm AEST

## NEW ASTHMA GUIDELINES: WHAT'S CHANGED?

# NEW ASTHMA GUIDELINES: WHAT'S CHANGED?

**The learning outcomes of interdisciplinary discussion are:**

- ▶ Outline guideline changes for adults and adolescents to improve the treatment of mild asthma
- ▶ Utilise clinical assessment and patient education to support decisions about treatment options for mild asthma
- ▶ Describe the new place in therapy of budesonide+formoterol for effective treatment of mild asthma in adults and adolescents




# DISCLOSURE

Prof Amanda Barnard has received funding from AstraZeneca to attend research conference in Bucharest, Romania, 2019.

Debbie Rigby has received speaker remuneration, advisory board fees and travel expenses from AstraZeneca.

# TREATMENT OPTIONS FOR ASTHMA IN ADULTS AND ADOLESCENTS






# PEOPLE WITH MILD ASTHMA

- ▶ Have fewer symptoms, however are the largest subgroup, accounting for up to 75% of total asthma cohort
- ▶ Are still at risk of acute exacerbations and fatal asthma attack
- ▶ Guidelines recommend using inhaled corticosteroids (ICS) for asthma control and to reduce risk of exacerbations
- ▶ Regular ICS adherence can be challenging

# TREATMENT OPTIONS FOR MILD ASTHMA IN ADULTS AND ADOLESCENTS



# TREATMENT OPTIONS FOR MILD ASTHMA IN ADULTS AND ADOLESCENTS


- ▶ SABA as needed for only a few people
  - ◆ Consider only if symptoms less than twice a month and no risk factors for flare-ups
- ▶ For people with
  - ◆ asthma symptoms twice or more during the past month
  - ◆ waking due to asthma symptoms once or more during the past month
  - ◆ an asthma flare-up in the previous 12 months

## Prescribe

- regular daily maintenance ICS (low dose) plus SABA as needed, OR
- budesonide+formoterol (low dose) reliever therapy as needed

# SELECTING OPTIONS

- ▶ History of flare-ups and exacerbations
- ▶ Day-to-day symptoms
- ▶ Patient preferences for treatment
- ▶ Potential issues with adherence
- ▶ Ability to use specific inhaler devices
- ▶ Cost
- ▶ Potential adverse effects



# CLINICAL EVIDENCE SUPPORTING THE GUIDELINE CHANGES

## ► SYGMA 1

- ◆ Budesonide+formoterol as needed had greater odds of achieving well-controlled asthma weeks (WCAW) versus SABA as needed ( $P = 0.046$ )

## ► SYGMA 2

- ◆ No significant difference for severe asthma exacerbations (annualised rate), when comparing budesonide+formoterol as needed versus ICS and SABA as needed

## ► Novel START

- ◆ Rate of asthma exacerbations for budesonide+formoterol as needed was significantly lower than SABA as needed ( $p < 0.001$ ), but did not differ significantly from ICS and SABA as needed

## ► PRACTICAL

- ◆ Severe asthma exacerbations were lower for budesonide+formoterol as needed, compared to ICS and SABA as needed ( $p = 0.049$ ).

# BUDESONIDE+FORMOTEROL RELIEVER THERAPY: NEW OPTION FOR MILD ASTHMA

- ▶ Recommended in updated Australian Asthma Handbook for level 2 treatment as an alternative to regular ICS (plus SABA as needed)
- ▶ PBS-listed on 1 June 2020 for people with asthma who require anti-inflammatory reliever therapy
- ▶ Not indicated for maintenance therapy
- ▶ Only two budesonide+formoterol products can be used as needed for symptom relief:
  - ◆ 200/6 micrograms dry-powder inhaler (Symbicort Turbuhaler, DuoResp Spiromax)
    - 1 inhalation per dose (maximum 12 per day)
  - ◆ 100/3 micrograms metered-dose inhaler (Symbicort Rapihaler)
    - 2 inhalations per dose (maximum 24 per day)

# A CASE: BETH WITH MILD ASTHMA

- ▶ Beth is a 32-year-old woman, who was referred by her community pharmacist to see you.
- ▶ She was diagnosed with asthma four years ago.
- ▶ Initially prescribed daily medium dose of an ICS plus as-needed reliever.
- ▶ She has been off maintenance inhaler therapy for more than a year and has had no exacerbation in the last year.
- ▶ She says she is symptom-free today and uses Ventolin once a week.

# RESOURCES

## Health professionals

- ▶ National Asthma Council Australia:
  - [Australian Asthma Handbook](#)
  - [How to device videos](#)
  - [Spirometry training and tools](#)
  - [Asthma action plans](#)
- ▶ Asthma Australia:  
[Asthma Connect](#) program connecting health professionals with the most current asthma management services, resources and opportunities
- ▶ RADAR article: [Budesonide with formoterol for mild asthma: New PBS listings](#)

## Patients

- ▶ National Asthma Council Australia:
  - [My Asthma Guide](#)
  - [Written Asthma Action Plans](#)
  - [Inhaler technique videos](#)
- ▶ [Asthma Australia](#) - coming soon, consumer guide to asthma guidelines
- ▶ Speak to an asthma educator:  
1800 278 462
- ▶ NPS MedicineWise consumer resources:
  - [Asthma explained](#)
  - [Medicines for treating asthma](#)
  - [MedicineWise app](#)

# REFERENCES

National Asthma Council Australia. Australian Asthma Handbook, Version 2.1. National Asthma Council Australia, Melbourne, 2020. Website. Available from: <http://www.asthmahandbook.org.au> (accessed 2 Sep 2020).

Dusser D, Montani D, Chanez O'Byrne P, et al. Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy 2007; 62: 591–604

O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med 2018;378:1865-76.

Bateman ED, Reddel HK, O'Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med 2018;378:1877-87.

Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med 2019;380:2020-30.

Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet 2019;394:919-28.

Pharmaceutical Benefits Scheme. PBS Schedule: Summary of Changes (June 2020). Canberra: Australian Government Department of Health, 2020 <http://www.pbs.gov.au/publication/schedule/2020/06/2020-06-01-general-soc.pdf> (accessed 2 Sep 2020).